27 Jul 2015 07:41
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Imperial Innovations Group Share News (IVO)
IVO Share
Price
IVO Share
News
IVO Share
Chat
IVO Share
Trades
IVO
Live RNS
IVO Share
Charts
IVO Broker
Ratings
IVO Directors
Deals
IVO Financial
Diary
IVO
Fundamentals
IVO Short
Positions
IVO
Media
Imperial Innovations Group Information
- There is currently no data for IVO
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Imperial Innovations invests £5.1m in new biotech start-up
Wed, 21st Sep 2016 12:23
(ShareCast News) - AIM-listed technology investor Imperial Innovations invested £5.1m in Artios Pharma, a new biotech start-up launched on Wednesday.Imperial Innovations contributed £5.1m to the £25m series A funding round, giving it a 14.9% interest in the new Cambridge- based company.Artios, which is backed by a syndicate of leading European and US life science investors including SV Life Sciences, Merck Ventures, Arix Bioscience PLC, CRT Pioneer Fund and AbbVie Ventures, will build a pipeline of DNA damage response therapies from Cancer Research UK and other global companies, and progress its Pol-theta enzyme programme.Bobby Soni, director of healthcare ventures at Imperial Innovations, said: "Targeting the DNA damage response is an exciting and promising field of biology."DNA damage response drug products have generated considerable interest following the recent clinical successes of PARP inhibitors which have highlighted the potential for DNA damage response drugs to cause selective death in cancer cells."The new company, which was formed with assets from Cancer Research Technology, the technology transfer unit of Cancer Research UK, is led by Dr. Niall Martin, who was co-founder and chief operating officer of MissionTherapeutics, another Cambridge-based drug discovery company which Imperial Innovations has also invested in.Shares in Imperial Innovations were up 0.78% to 447.20p at 1153 BST.
More News
2 Jul 2015 23:01
For first time, gene therapy shows promise in cystic fibrosis
By Kate Kelland LONDON, July 3 (Reuters) - Scientists conducting a major trial of a therapy that replaces the faulty gene responsible for cystic fibrosis say the treatment has showed significant benefit for the first time in patients' lung function. The technique, developed with the t
Read more2 Jul 2015 09:49
Imperial Innovations and Mercia Technologies invest in aluminium business
AIM listed firms Imperial Innovations and Mercia Technologies have together provided £4m to aluminium business Impression Technologies. The duo invested £2.5m and £1.5m respectively in the firm which makes aluminium components for the transport sector. The investment brings Imperial Innovation's s
Read more30 Jun 2015 16:26
Imperial Innovations invests £3m in Abingdon, brings stake to over 30%
British technology transfer and commercialisation company Imperial Innovations Group said it has invested £3m in portfolio company Abingdon Health. On Tuesday, the London-listed group said that, along with existing investors, it had invested £2.5m in Abingdon and now holds a 33.7% stake in the busin
Read more25 Jun 2015 10:17
London mayor suggests $15 bln 'megafund' to boost biotech
LONDON, June 25 (Reuters) - Banks, investors and big drug companies should consider creating a 10-billion-pound ($15.7 billion) "megafund" to help biotech firms in London and across Britain compete with U.S. rivals, London mayor Boris Johnson said on Thursday. Britain is a leader in academi
Read more29 May 2015 15:31
Imperial Innovations' portfolio company appoints new executive chairman
Technology investment group Imperial Innovations Group has appointed Paolo Paoletti as executive chairman of its portfolio company Kesios Therapeutics. London-based Kesios, which develops novel therapeutics for cancer treatments, was created to develop and commercialise certain research from the Dep
Read more